Resaca

AHCC (Active Hexose Correlated Compound), a standardized alpha-glucan extract from cultured Lentinula edodes mycelia, has demonstrated immunomodulatory activity in clinical studies including increased NK-cell activity. Studies show it reduces infection susceptibility and has shown evidence of reducing serious respiratory infections including pneumonia in immunocompromised patients. Preclinical studies show improved survival in H1N1 influenza pneumonia.

Allicin, the principal organosulfur antimicrobial from garlic, has demonstrated vapor-phase killing of MDR Streptococcus pneumoniae, Pseudomonas aeruginosa, and other major lung pathogens in EUCAST-standard testing. It inhibits P. aeruginosa biofilm formation and virulence factors central to pneumonia pathogenesis. Historical records document garlic vapor inhalation for pulmonary infections in the pre-antibiotic era.

Andrographis paniculata has been studied in RCTs and a systematic meta-analysis for acute respiratory tract infections, demonstrating significant improvement in cough, sore throat, and overall symptoms versus placebo. A retrospective cohort study in Thailand examined its association with reduced pneumonia risk in mild COVID-19 patients. Andrographolide, its active compound, showed significant anti-bacterial pneumonia effects in animal models via pulmonary delivery and by suppressing NF-κB-driven lung inflammation.

Andrographolide is the principal bioactive diterpenoid from Andrographis paniculata with direct evidence in pneumonia-relevant animal models. It significantly attenuates lung injury in both S. aureus and Klebsiella pneumoniae pneumonia. Oral andrographolide tablets are clinically used in China for respiratory tract infections. It modulates NF-κB and cytokine production central to pneumonia pathophysiology.

Astragaloside IV (AS-IV), the primary bioactive saponin of Astragalus membranaceus, has demonstrated antiviral and anti-inflammatory activity in viral pneumonia animal models. It is identified in a 2025 Virology Journal systematic review as a candidate for antiviral drug development and adjuvant therapy for viral respiratory diseases. AS-IV modulates lung endothelial integrity and cytokine responses in acute lung injury.

Astragalus membranaceus has clinical RCT and systematic review evidence for preventing respiratory infections and reducing radiation-induced pneumonia. Its polysaccharides and astragalosides are identified as potential antiviral adjuvants for viral respiratory diseases in a 2025 Virology Journal systematic review. Traditional Chinese medicine has used it as a primary lung Qi tonic for over 2,000 years.

Propolis is a resinous beehive product with broad-spectrum antimicrobial and antiviral properties reviewed across 158 publications for respiratory tract diseases. A clinical study in COVID-19 pneumonia patients showed green Brazilian propolis produced earlier viral clearance and reduced mortality versus standard care. Propolis inhibits SARS-CoV-2 via multiple mechanisms and is active against secondary bacterial lung infection pathogens.

Berberine, an isoquinoline alkaloid from Berberis and Coptis species, has demonstrated antiviral activity against influenza A (H1N1) in animal lung infection models, reducing viral titer and improving survival. It is a component of traditional Chinese medicine pneumonia treatment protocols referenced in China's COVID-19 Treatment Program. Mechanistic studies support its activity against pneumonia-associated pulmonary fibrosis via TNF-α, IL-6, and STAT3 pathways.

Cordyceps militaris was evaluated in a randomized, double-blind, placebo-controlled trial as adjuvant therapy in mild-to-moderate COVID-19 pneumonia, showing shorter time to clinical recovery and higher recovery rates versus placebo. Traditional Chinese medicine has used Cordyceps for lung conditions for over 1,000 years. It increases oxygen utilization efficiency relevant to pneumonia-induced hypoxia.

Curcumin, the principal polyphenol from turmeric, has demonstrated anti-inflammatory properties directly relevant to pneumonia via NF-κB inhibition and cytokine storm modulation. It is identified among natural antioxidants with therapeutic potential against COVID-19 viral pneumonia. Preclinical evidence supports its role in reducing lung inflammation in pneumonia models.

Echinacea has clinical evidence from meta-analyses for reducing acute respiratory tract infection incidence, duration, and antibiotic usage. German Commission E, WHO, and Health Canada have endorsed its use for respiratory infections. Traditional use for lower respiratory conditions and pneumonia supportive care spans Native American and European herbal medicine.

Echinacea purpurea has the strongest clinical evidence among Echinacea species for acute respiratory infections, with a systematic meta-analysis of nine studies confirming reduced URTI incidence, duration, and antibiotic usage in children. German Commission E and WHO positively evaluated it. A randomized trial demonstrated an E. purpurea, propolis, and vitamin C preparation significantly prevented respiratory infections in children aged 1–5.

EGCG, the principal catechin from green tea, has demonstrated direct antimicrobial activity against Streptococcus pneumoniae and antiviral activity against influenza and SARS-CoV-2. It inhibits pneumococcal adhesion to host cells and modulates pneumonia-associated inflammatory cascades through NF-κB and NLRP3 inhibition. It is a documented antiviral component in propolis-related COVID-19 pneumonia research.

Eucalyptus (Eucalyptus globulus) and its principal compound 1,8-cineole showed antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae in EUCAST-tested vapor-phase studies. EMA approved eucalyptus oil preparations for respiratory tract congestion. Clinical and pharmacological reviews confirm anti-inflammatory, antibacterial, and antiviral respiratory activities.

Forsythia suspensa is traditionally and pharmacologically documented for the treatment of pneumonia, acting via anti-inflammatory and antiviral mechanisms. Forsythoside A has been shown to protect against LPS-induced acute lung injury and RSV-induced pneumonia in mouse models. Combination TCM formulas containing Forsythia have been used clinically in China for pneumonia, including COVID-19.

Fritillary preparations are used clinically in TCM for pneumonia, and pharmacological evidence supports anti-pneumonic mechanisms including anti-inflammatory, antibacterial, and immunomodulatory activity. FRC holds documented clinical significance for pneumonia. Traditional texts list pneumonia as an indication of both Chuan Bei Mu and Zhe Bei Mu.

Garlic (Allium sativum) and its active compound allicin demonstrated direct in vitro antibacterial activity against Streptococcus pneumoniae and Klebsiella pneumoniae at quantified MICs. Allicin vapor inhibits MDR lung pathogens in EUCAST-standard testing. Garlic has been used traditionally across cultures for respiratory infections, with historical records of pneumonia and tuberculosis treatment by garlic vapor inhalation.

Ginseng (Panax ginseng) is cited in authoritative phytotherapy reviews as showing promise for respiratory diseases including pneumonia, with ginsenosides demonstrating immunomodulatory and antiviral properties. RCTs have studied Korean red ginseng for prevention of respiratory infections. Traditional East Asian medicine has used ginseng for lung deficiency and respiratory conditions for over 2,000 years.

Glycyrrhizin, the principal triterpenoid saponin from licorice root, demonstrated antiviral activity against SARS-CoV, influenza, RSV, and other respiratory pathogens; a Lancet 2003 study identified it as one of the most active natural compounds against SARS-CoV in vitro. It is a component of licorice-containing TCM formulas used in SARS and COVID-19 pneumonia protocols and suppresses NF-κB and AP-1 to reduce pneumonia-associated lung inflammation.

Green tea catechins, particularly EGCG, have demonstrated antimicrobial activity against Streptococcus pneumoniae and antiviral activity against respiratory viruses. Green tea appears in authoritative phytotherapy reviews for respiratory disease management including pneumonia. Traditional East Asian medicine uses green tea for respiratory infections and lung conditions.

Honey has broad-spectrum antimicrobial, antiviral, and anti-inflammatory properties with evidence in viral pneumonia contexts. A clinical study in COVID-19 patients showed honey plus Nigella sativa produced earlier viral clearance and reduced mortality versus standard care. NICE and PHE recommend honey as first-line treatment for acute cough from upper respiratory infection.

Luteolin attenuates lung inflammation in bacterial and viral pneumonia models through NF-κB, TLR4, and NLRP3 inflammasome suppression. It reduces pro-inflammatory cytokine production and oxidative stress in lung tissue. Evidence is preclinical.

NAC has RCT evidence for improving oxidative stress and inflammatory markers in community-acquired pneumonia and for preventing ventilator-associated pneumonia (VAP). A randomized double-blind placebo-controlled trial demonstrated NAC 600 mg twice daily significantly reduced VAP incidence in ICU patients. A 2018 RCT found NAC reduced plasma MDA and TNF-α in CAP patients versus conventional treatment alone.

Quercetin is a flavonoid with antiviral, anti-inflammatory, and immunomodulatory properties investigated for COVID-19 pneumonia. It is a key bioactive antiviral component in propolis active against SARS-CoV-2 and respiratory pathogens. Preclinical studies show it reduces lung inflammation in bacterial and viral pneumonia models via NF-κB and NLRP3 inhibition.

Thyme (Thymus vulgaris) essential oil demonstrated antimicrobial activity against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in EUCAST-standard testing. EMA and German Commission E approved thyme for acute bronchitis. A respiratory infection case report included a Thymus-containing EO mixture that reduced oxygen requirement in RSV pneumonia in a pediatric patient.

Vitamin C has clinical evidence as an adjunct in pneumonia: studies found it mitigates oxidative stress and proinflammatory mediators in severe community-acquired pneumonia. A WHO-referenced systematic review identified two small studies finding reduced time to symptom resolution in severe pediatric pneumonia. Vitamin C also reduces pneumonia incidence in high-physical-stress populations based on systematic review evidence.

Vitamin D has RCT evidence for reducing time to improvement in severe pneumonia in vitamin D-deficient children given a high-dose (100,000 IU). Meta-analyses establish vitamin D deficiency as an independent risk factor for pneumonia. Supplementation reduces acute respiratory tract infection incidence in deficient populations and is studied in Cochrane reviews for COVID-19 pneumonia.

Zinc supplementation (20 mg/day) has been shown in clinical evidence to accelerate recovery from severe pneumonia in children. Multiple systematic reviews support zinc's role in reducing pneumonia and respiratory tract infection incidence, particularly in elderly and children. Evidence is mixed for hospitalized severe pediatric pneumonia, but strongly supportive for community-based pneumonia prevention.

S. cusia leaf (Da-Ching-Yeh) is specifically cited in TCM sources as a treatment for viral pneumonia, epidemic encephalitis B, and related infectious respiratory conditions. This traditional indication is consistently documented across multiple ethnobotanical and pharmacological reviews.

Early American settlers used boneset to treat pneumonia, as documented in historical sources. Drugs.com's clinical monograph records that 'the early settlers used the plant to treat rheumatism, dropsy, dengue fever, malaria, pneumonia, and influenza.' Traditional use also documents its role in preventing pulmonary complications during influenza. No clinical trials for boneset in pneumonia exist.

Ginger (Zingiber officinale) is used in Ayurvedic, Chinese, and Middle Eastern traditional medicine for respiratory infections and chest congestion. Authoritative phytotherapy reviews cite it for respiratory disease management. Active compounds gingerols and shogaols provide anti-inflammatory and antimicrobial properties relevant to pneumonia supportive care.

Honeysuckle has been used in folk and TCM prescriptions for pneumonia, and stems combined with flowers are used as an infusion for upper respiratory tract infections including pneumonia. Documented antimicrobial activity against Streptococcus pneumoniae and antiviral properties provide mechanistic support.

Hyssop is documented in traditional Iranian medicine (ITM) as a treatment for pneumonia and inflammatory lung diseases. ScienceDirect's ITM overview cites its use for cold catarrh, pneumonia, cough, and asthma.

Licorice root (Glycyrrhiza glabra/uralensis) has been used in traditional Chinese, Ayurvedic, and European herbal medicine as an expectorant, anti-inflammatory, and respiratory demulcent for coughs, bronchitis, and lung infections including pneumonia. Glycyrrhizin has demonstrated antiviral properties against SARS-CoV and influenza. It is universally present in TCM pneumonia formulas.

Eclectic physicians used lobelia as both an internal expectorant/antispasmodic and a topical chest plaster (Compound Emetic Powder) for pneumonia. Felter's Eclectic Materia Medica and ADAM both document this use. No modern clinical evidence supports lobelia for pneumonia.

Mullein (Verbascum thapsus) has been used since ancient times across Europe, Asia, and North America as an expectorant and demulcent for pneumonia, asthma, and pulmonary diseases. In vitro antibacterial studies demonstrate activity against Klebsiella pneumoniae, S. aureus, and drug-resistant Streptococcus pneumoniae. Saponins provide expectorant action and mucilage soothes inflamed respiratory membranes.

Mustard chest plasters were traditionally used as an adjunct treatment for pneumonia, with historical records documenting physician-prescribed use in the early 20th century. The proposed mechanism is increased chest circulation and mucus loosening. No modern evidence supports efficacy in pneumonia.

Peppermint (Mentha x piperita) essential oil has demonstrated antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae in EUCAST-referenced testing. Clinical and pharmacological reviews confirm anti-inflammatory, antibacterial, and antiviral activities relevant to respiratory ailments. EMA has monographed peppermint for symptomatic relief of respiratory congestion.

Platycodon root has been used in TCM for lung carbuncle and bacterial lung infections historically equivalent to pneumonia. Modern Chinese clinical experience documents its role in treating 'plum pneumonia' (lobar pneumonia). The Chinese Pharmacopoeia's indication for lung abscess with purulent sputum overlaps directly with pneumonia management.

Reishi (Ganoderma lucidum), known as the Mushroom of Immortality in TCM, has been used for over 2,000 years for lung conditions and is cited in phytotherapy reviews for immune support in respiratory infections. Beta-glucans and triterpenoids activate macrophages and NK cells, while preclinical studies show lung-protective activity. No direct clinical RCTs for pneumonia exist.

Turmeric (Curcuma longa) has been used in Ayurvedic and traditional Chinese medicine for respiratory infections, lung congestion, and inflammatory chest conditions associated with pneumonia. Phytotherapy reviews cite turmeric for reducing lung inflammation and improving airway clearance. Active curcuminoids provide anti-inflammatory NF-κB inhibition relevant to pneumonia pathophysiology.